Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 8/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.45 |
| ▸ | KIT | P10721 | 7/20 | 0.45 |
| ▸ | ULK1 | O75385 | 4/20 | 0.44 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496547 | 0.94 | BRD4 (0.46) | BRD4SYKALKFLT3CHEK1 | |
| SCHEMBL1743374 | 0.94 | BRD4 (0.49) | BRD4SYKALKFLT3CHEK1 | |
| SCHEMBL3494581 | 0.90 | BRD4 (0.53) | BRD4SYKFLT3CHEK1KIT | |
| SCHEMBL3494040 | 0.90 | CHEK1 (0.45) | SYKALKFLT3CHEK1KIT | |
| SCHEMBL1741119 | 0.90 | BRD4 (0.48) | BRD4SYKALKFLT3CHEK1 | |
| SCHEMBL1741976 | 0.88 | BRD4 (0.48) | BRD4SYKALKFLT3CHEK1 | |
| SCHEMBL13268479 | 0.88 | BRD4 (0.55) | BRD4SYKALKFLT3JAK3 | |
| SCHEMBL13248984 | 0.87 | SYK (0.46) | BRD4SYKALKFLT3JAK3 | |
| SCHEMBL13248971 | 0.86 | SYK (0.46) | BRD4SYKALKFLT3JAK3 | |
| SCHEMBL3494973 | 0.86 | SYK (0.46) | BRD4SYKALKFLT3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2387402-A2 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8038799-B2 | Substrate processing apparatus and substrate processing method | KURITA WATER INDUSTRIES LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083240-A2 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | BRD4 1173/4885SYK 460/4885ALK 582/4885 |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | IL2, IL17A, IL23R | BRD4 664/4885SYK 1196/4885ALK 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.